PT
PTGX
HealthcareProtagonist Therapeutics, Inc.
Price Chart
Loading...
Market Data
Revenue TTMXBRL
—
Net IncomeXBRL
—
Gross MarginXBRL
—
EPS (Diluted)XBRL
—
No analysis generated yet. Run the pipeline for this company.
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
8
EarningsBullishPer-CompanyMay 5, 2026
Protagonist Therapeutics receives $50M milestone payment following FDA approval of icotrokinra
- ▸ICOTYDE (icotrokinra) FDA approved for moderate-to-severe plaque psoriasis in March
- ▸Received $50 million milestone payment from partnership
- ▸Eligible for up to $580 million in additional future milestone payments
- ▸Entitled to tiered royalties ranging from 6% to 10% on net sales
- ▸Q1 2026 financial results and corporate update provided
8
RegulatoryBullishPer-CompanyMar 20, 2026
FDA approves JNJ's Icotyde for plaque psoriasis, benefiting partner Protagonist Therapeutics
- ▸FDA approved Icotyde (icotrokinra) for moderate-to-severe plaque psoriasis
- ▸Icotyde indicated for adults and pediatric patients aged 12 and older
- ▸PTGX shares rose 4.7% following the regulatory approval announcement
- ▸Icotyde currently under evaluation for psoriatic arthritis, ulcerative colitis, and Crohn's disease
- ▸Upcoming quarterly revenue expected at $5M, down 82.3% year-over-year
9
ProductBullishPer-CompanyMar 18, 2026
FDA approves ICOTYDE for plaque psoriasis, triggering $50M milestone for Protagonist Therapeutics
- ▸FDA approved ICOTYDE (icotrokinra) for moderate to severe plaque psoriasis
- ▸Approval triggers $50 million milestone payment to Protagonist Therapeutics
- ▸Protagonist eligible for up to $580 million in future milestone payments
- ▸Protagonist to receive tiered royalties ranging from 6% to 10% on global sales
- ▸ICOTYDE is the first and only IL-23R targeted oral peptide